Non-Nucleoside Analogue Reverse Transcriptase Inhibitors (NNRTIs)
(Last updated:2/12/2014; last reviewed:2/12/2014)
The International Antiviral Society-USA (IAS-USA) maintains a list of updated resistance mutations (see
Rilpivirine is approved in combination with other ARV agents for treatment-naive, HIV-infected adults with viral load ≤100,000 copies/mL. The pharmacokinetics, safety, and efficacy of rilpivirine in pediatric patients have not been established. An international trial currently under way is investigating a 25-mg dose of rilpivirine in combination with two nucleoside reverse transcriptase inhibitors in antiretroviral-naive children aged 12 to <18 years who weigh ≥32 kg and have a viral load ≤100,000 copies/mL.